New Biomarkers Will Revolutionize Clinical Practice for Early Onset Alzheimer’s and Dementia

At this year’s Neurologipäivät, Eino Solje, an associate professor and research director in neurology, discussed the value of new biomarkers for the early diagnosis of Alzheimer’s and other forms of dementia. He highlighted p-tau217, a biomarker that will soon be available in clinical practice. This could improve early detection of these diseases and reduce reliance on expensive testing methods.